Brussels: Europe has decided that it can no longer treat the supply of critical medicines as someone else’s problem, and lawmakers spent the first half of 2026 turning that conviction into law. The Council and the Parliament reached a provisional agreement on the Critical Medicines Act in May, and the Parliament has since backed the text, moving the union closer to a durable answer to years of shortages.

The scale of the problem drove the urgency. More than half of recent critical medicine shortages across the EU traced back to manufacturing failures, and the continent leans heavily on active pharmaceutical ingredients produced in India and China. When a single plant stumbles or a government restricts exports, pharmacies from Lisbon to Helsinki feel the gap within weeks.

What the law actually changes

The Act reaches for three levers at once. It pushes member states to diversify supply chains for essential drugs, it makes joint procurement easier so smaller countries can pool their buying power, and it channels support toward manufacturing capacity for finished medicines and their ingredients inside Europe. The Council’s framework treats resilience as an industrial goal, not merely a health one.

One provision marks a genuine break with the past. In public tenders for critical medicines, the agreed rules require resilience criteria to outweigh price. Cheap supply from a single distant source will no longer win contracts on cost alone, a change that could reshape how national health systems buy antibiotics, insulin and painkillers.

Why the evidence favours caution as much as ambition

The research base supports the diagnosis, yet it also warns against expecting quick relief. Rebuilding domestic production of generic drugs and their chemical precursors takes years and steady demand, because manufacturers will not invest in plants that governments might abandon once the next crisis fades. The Act supplies the political signal, but factories follow contracts, not communiques.

Cost sits at the centre of the trade-off. Medicines made closer to home will often carry higher prices than those shipped from Asia, and squeezed health budgets must decide how much security is worth. Analysts who study drug supply chains argue that a modest premium buys insurance against the far larger costs of a shortage, from cancelled surgeries to rationed treatment.

There is a global dimension the union cannot ignore. Critics warn that if Europe hoards manufacturing and stockpiles, lower-income countries in Africa and elsewhere could find themselves further back in the queue when supplies tighten. A strategy built on European resilience carries an obligation to avoid worsening scarcity beyond the continent’s borders.

Supporters of the Act counter that a Europe unable to make its own antibiotics is a Europe perpetually exposed, and that dependence on a handful of foreign plants is itself a strategic vulnerability. They point to the pandemic and to recent export limits as proof that markets alone will not guarantee supply when panic sets in.

The honest verdict is that the law fixes an incentive problem it cannot fully solve on its own. It tells companies that resilience will be rewarded and tells governments that price is no longer the only measure, but whether pharmacies stay stocked will depend on sustained funding, credible demand and cooperation that survives the next budget round. Europe has written the prescription; filling it will take the rest of the decade.